Piper Sandler Initiates Coverage On Climb Bio with Overweight Rating, Announces Price Target of $23
Benzinga Newsdesk 9 months ago
NewsPrice TargetInitiationAnalyst Ratings
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Climb Bio (NASDAQ:CLYM) with a Overweight rating and announces Price Target of $23.
Piper Sandler analyst Yasmeen Rahimi initiates coverage on Climb Bio (NASDAQ:CLYM) with a Overweight rating and announces Price Target of $23.